Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.4 , No. 2, Publication Date: Feb. 27, 2018, Page: 13-16
 in stage IIIb or IV after treatment with CIMAvax-EGF® vaccine in the Primary Health Care of Ciego de Avila province was evaluated. An observational and descriptive retrospective study was carried out. The medical record of the patients included in a phase IV clinical trial were analyzed. The universe comprised 76 patient evaluated and the sample was 35 who often accomplish the inclusion criteria. The results were presented in tables. The median of survival was determinate. The median of survival to diagnosis was 18 months for patients in IIIb stage who received first line treatment and 6 months for patients who did not receive this therapy. In the patient in IV stage the survival was 14 and 5 months respectively. The survival median to inclusion was 6 and 5 months respectively for patient in IIIb stage who received or did not receive first line treatment and 5 and 3.5 months respectively for patients in IV stage. The survival was high in several months for patients with non-small cell lung cancer advanced who received first line treatment for their disease.&picture=http://www.aascit.org/aascit/decorators/img/journal/893.jpg)
| [1] | Thayde Trujillo Tirado, Department National Network of Clinical Trials, Clinical Trials Coordinating National Center, Ciego de Avila, Cuba. |
| [2] | Giselle Veguilla Alomar, Department National Network of Clinical Trials, Clinical Trials Coordinating National Center, Ciego de Avila, Cuba. |
| [3] | Odelaine Guzmán Pérez, Clinical Trials Department, North Polyclinic, Ciego de Avila, Cuba. |
| [4] | Iliana Pérez Chong, Medical Assistance Department, Raul Ortiz Polyclinic, Ciro Redondo, Cuba. |
| [5] | Lesyani López Legrá, Medical Assistance Department, Raul Ortiz Polyclinic, Ciro Redondo, Cuba. |
| [6] | Olegario Rubén Sánchez Real, Medical Assistance Department, North Polyclinic, Moron, Cuba. |
In 2015 cancer was the second cause of death in Cuba and the first cause in Ciego de Avila. The bronchus, trachea and lung tumors were the most frequent. The global survival of patient with non-small cell lung cancer (NSCLC) in stage IIIb or IV after treatment with CIMAvax-EGF® vaccine in the Primary Health Care of Ciego de Avila province was evaluated. An observational and descriptive retrospective study was carried out. The medical record of the patients included in a phase IV clinical trial were analyzed. The universe comprised 76 patient evaluated and the sample was 35 who often accomplish the inclusion criteria. The results were presented in tables. The median of survival was determinate. The median of survival to diagnosis was 18 months for patients in IIIb stage who received first line treatment and 6 months for patients who did not receive this therapy. In the patient in IV stage the survival was 14 and 5 months respectively. The survival median to inclusion was 6 and 5 months respectively for patient in IIIb stage who received or did not receive first line treatment and 5 and 3.5 months respectively for patients in IV stage. The survival was high in several months for patients with non-small cell lung cancer advanced who received first line treatment for their disease.
Keywords
Non-small Cell Lung Cancer, NSCLC, Median of Survival, CIMAvax-EGF®, IIIb Stage, IV Stage
Reference
| [01] | Martínez Feria Francisco, Acosta Brooks Soraida Cándida, Cobián Caballero Carlos Oliver. Progression-free survival in non-small cell lung cáncer in patients vaccinated with CIMAvax-EGF. MEDISAN. 2015 Dic [citado 2016 Mayo 17]; 19 (12): 1485-1491. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192015001200007&lng=es. |
| [02] | Ministerio de Salud Pública. Anuario Estadístico de Salud 2015 [Internet]. La Habana. MINSAP; 2015 [cited 2016 May 17]. Available from: http//files.sld.cu/dne/files/2016/04/anuario_2015_electronico-1.pdf |
| [03] | Statistical report for Department of hospitals. DPS Ciego de Ávila, nov-2013. |
| [04] | Bender E. Epidemiology: the dominant malignancy. Nature 2014 sept 11. 513: S2-S3. Available from: http://www.nature.com/nature/journal/v513/n7517_supp/full/513S2a.html |
| [05] | Díaz García Y, Bello Ulloa L, Cabrera Villadons D, Delgado Moya R. Epidemiology of lung cancer in the "Dr. Antonio Luaces Iraola" provincial hospital of Ciego de Avila. MEDICIEGO 2013 [cited 2016 May 17]; 19 (Supl. 1). Available from: http://bvs.sld.cu/revistas/mciego/vol19_supl1_2013/articulos/t-4.html |
| [06] | Haithan S.; Abu-Lebdeh; Mark T Andolina; Tracy T. Barchelor; et al. Manual de quimioterapia del cáncer. 8th Edition. LIPPINCOT WILLIAMS & WILKINS, 2011. Available from: https://www.google.com.cu/webhp?ie=utf-8&oe=utf-8&gws_rd=cr&ei=_j5xV7DDEIO3eYOgj1A#q=manual+de+quimioterapia+del+cancer |
| [07] | Rodríguez Pedro C, Rodríguez Gryssell, González Gisela, Lage Agustín. Clinical development and prospects of the vaccine CIMAvax EGF in the treatment of non-small cell lung cancer. MEDICC Review [Internet] 2010 Winter [cited 2016 May 17]; 12 (1). Available from: http://www.medicc.org/mediccreview/index.php?issue=11&id=128&a=vahtml |
| [08] | Abreu Rivera P, Labrada Betancourt Y, Sánchez Escalona JL, Alvares Zaldívar J. Evaluation of survival of lung cancer patients treated with the vaccine of epidermal growth factor. CorrCientMédHolg. 2011 [cited 2016 Mayo 17]; 15 (1). Available from: http://www.cocmed.sld.cu/no151/no151ori08.htm |
| [09] | Blog Vidasana CUN [Internet]. Lung cancer. Symptoms, Types, treatment and life expectancy. Vidasana Clinica Navarra University. Previsora Bilbaina Insurance 2017® Group - [Cited 2017 jul 10]. Available from: http://www.enmanosdelosmejores.com/blog/blog-articulo.asp?id=119 |
| [10] | Therapeutic positioning report of afatinib (Giotrif®) in non-small cell lung cancer. Spanish Agency for Medicinal Products and Medical Devices; 2015 march 12. PT-AFATINIB/V1/12032015. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-afatinib-giotrif.pdf |
| [11] | Soler D.; Silva JA; Tabío Y; Batista M; Gamboa L; Loforte N. Evaluation of therapeutic vaccine in patients with advanced lung cancer treated in Primary Health Care.. RevInfCient 2014 [cited 2016 May 17]; 85 (3). Available from: http://www.gtm.sld.cu/imagen/RIC/Vol_85_No.3/evaluacion_de_vacuna_terapeutica_pacientes_cancer_pulmon_tc.pdf |
| [12] | Cobián Caballero Carlos Oliver, Acosta Brooks Soraida Cándida, Martínez Feria Francisco, Romero García Lázaro Ibrahim. Survival in patients with non-small cell lung cancer vaccinated with CIMAvax-EGF. MEDISAN [Internet]. 2016 Mar [cited 2016 Jun 27]; 20 (3): 320-328. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192016000300007&lng=es. |
